Cowen and Company’s BridgeBio Pharma BBIO Stock Holding History

Cowen and Company’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,000	Closed	-$47K	–	596
2021 Q2	$47K	Buy	26,000 +5,000	+24%	+$286K	﹤0.01%	410
2021 Q1	$32K	Buy	+21,000	New	+$1.37M	﹤0.01%	423
2020 Q4	–	Sell	-24,300	Closed	-$18K	–	412
2020 Q3	$18K	Sell	24,300 -15,700	-39%	-$494K	﹤0.01%	358
2020 Q2	$277K	Buy	+40,000	New	+$1.22M	0.05%	179

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cowen and Company's BBIO Position: Q1 2024 in Review

Cowen and Company sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 72,141 shares — an estimated $2.91M sold.

Cowen and Company first reported a position in BBIO in Q4 2023 and held it in 1 quarter. The position peaked at $2.91M in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Cowen and Company reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 72,141 BridgeBio Pharma shares in Q1 2024, an estimated $2.91M.
Cowen and Company first reported a position in BridgeBio Pharma in Q4 2023 and held it in 1 quarter.
Cowen and Company's BridgeBio Pharma position peaked at $2.91M in Q4 2023.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.